1. Home
  2. MIRM vs WTFCM Comparison

MIRM vs WTFCM Comparison

Compare MIRM & WTFCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • WTFCM
  • Stock Information
  • Founded
  • MIRM 2018
  • WTFCM N/A
  • Country
  • MIRM United States
  • WTFCM United States
  • Employees
  • MIRM N/A
  • WTFCM 5903
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • WTFCM Major Banks
  • Sector
  • MIRM Health Care
  • WTFCM Finance
  • Exchange
  • MIRM Nasdaq
  • WTFCM Nasdaq
  • Market Cap
  • MIRM 2.5B
  • WTFCM N/A
  • IPO Year
  • MIRM 2019
  • WTFCM N/A
  • Fundamental
  • Price
  • MIRM $50.30
  • WTFCM $24.97
  • Analyst Decision
  • MIRM Strong Buy
  • WTFCM
  • Analyst Count
  • MIRM 9
  • WTFCM 0
  • Target Price
  • MIRM $66.22
  • WTFCM N/A
  • AVG Volume (30 Days)
  • MIRM 468.1K
  • WTFCM N/A
  • Earning Date
  • MIRM 08-06-2025
  • WTFCM N/A
  • Dividend Yield
  • MIRM N/A
  • WTFCM N/A
  • EPS Growth
  • MIRM N/A
  • WTFCM N/A
  • EPS
  • MIRM N/A
  • WTFCM N/A
  • Revenue
  • MIRM $379,251,000.00
  • WTFCM N/A
  • Revenue This Year
  • MIRM $35.83
  • WTFCM N/A
  • Revenue Next Year
  • MIRM $16.83
  • WTFCM N/A
  • P/E Ratio
  • MIRM N/A
  • WTFCM N/A
  • Revenue Growth
  • MIRM 69.31
  • WTFCM N/A
  • 52 Week Low
  • MIRM $33.52
  • WTFCM N/A
  • 52 Week High
  • MIRM $54.23
  • WTFCM N/A
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 59.09
  • WTFCM 28.06
  • Support Level
  • MIRM $47.89
  • WTFCM $24.94
  • Resistance Level
  • MIRM $51.93
  • WTFCM $25.36
  • Average True Range (ATR)
  • MIRM 1.49
  • WTFCM 0.02
  • MACD
  • MIRM -0.25
  • WTFCM -0.05
  • Stochastic Oscillator
  • MIRM 59.65
  • WTFCM 5.95

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About WTFCM Wintrust Financial Corporation Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series D

Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. The company's operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.

Share on Social Networks: